Tarrah Davis
Family · Dunlap, TNNPI 1083228209
Payments from drug & device makers
Across 113 payments — averaging $42.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- AbbVie$522
- Amgen$337
- Novo Nordisk$257
- Lilly USA, LLC$219
- Novartis$161
- plus $2K from 27 others
What the payments were for
- Food & beverage$4,847100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 19 | $1,026 |
| AbbVie | 14 | $522 |
| Amgen(2 entities) | 5 | $337 |
| Novo Nordisk | 7 | $257 |
| Lilly USA, LLC | 12 | $219 |
| Novartis | 9 | $161 |
| Bayer | 7 | $160 |
| Bard Peripheral Vascular, Inc. | 1 | $146 |
| Silk Road Medical, Inc. | 1 | $137 |
| Boston Scientific | 1 | $131 |
| Kyowa Kirin, Inc. | 1 | $129 |
| Regeneron Healthcare Solutions, Inc. | 1 | $125 |
| Sanofi | 1 | $124 |
| Noah Medical Corporation | 1 | $124 |
| Mylan Specialty L.p. | 1 | $124 |
| Vertex | 1 | $120 |
| Sumitomo Pharma America, Inc. | 1 | $120 |
| GSK | 2 | $118 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $103 |
| Pharmacosmos Therapeutics Inc. | 1 | $101 |
| Phathom Pharmaceuticals, Inc. | 3 | $91 |
| Astellas Pharma US Inc | 3 | $87 |
| Pfizer | 4 | $74 |
| Axsome Therapeutics, Inc. | 1 | $56 |
| Xeris Pharmaceuticals, Inc. | 3 | $53 |
| Exact Sciences | 3 | $52 |
| Dexcom, Inc. | 2 | $38 |
| Corcept Therapeutics | 1 | $25 |
| Scilex Pharmaceuticals Inc. | 2 | $23 |
| Johnson & Johnson | 1 | $19 |
| Idorsia Pharmaceuticals US Inc | 1 | $19 |
| Esperion Therapeutics, Inc. | 1 | $14 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ENROUTE Transcarotid Neuroprotection System$274
- AIRSUPRA$228
- VENOVO$146
- ENROUTE Enflate Transcarotid RX Balloon Dilatation Catheter$137
- ENROUTE Transcarotid Stent$137
- WATCHMAN FLX$131
- DUPIXENT$125
- VRAYLAR$125
- ALTUVIIIO$124
- GALAXY$124
- Yupelri$124
- GEMTESA$120
- UBRELVY$114
- Otezla$104
- Repatha$103
- BREZTRI$102
- Monoferric$101
How this compares
$4,847 in reported general payments places this provider in the 90th percentile of 6,706 family providers in Tennessee.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 34 | $52,699 |
| FarxigaDapagliflozin Propanediol | 54 | $52,027 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 42 | $38,720 |
| OzempicSemaglutide | 29 | $35,986 |
| JardianceEmpagliflozin | 27 | $29,636 |
| EliquisApixaban | 28 | $26,601 |
| XareltoRivaroxaban | 15 | $19,761 |
| Tresiba Flextouch U-200Insulin Degludec | 15 | $16,979 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 17 | $13,207 |
| Breo ElliptaFluticasone/Vilanterol | 12 | $9,124 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $5,748 |
| Rosuvastatin Calcium | 162 | $3,107 |
| Losartan Potassium | 119 | $1,898 |
| Atorvastatin Calcium | 92 | $1,444 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 47 | $1,361 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Breztri Aerosphere | $1,026 | $65,23471 claims |
| Lilly USA, LLCMounjaro | $219 | $52,69934 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $118 | $47,84354 claims |
| Novo NordiskOzempic | $257 | $35,98629 claims |
| PfizerEliquis | $74 | $26,60128 claims |
| Johnson & JohnsonXarelto | $19 | $19,76115 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 6,706 family providers in Tennessee.
Other family in Dunlap
- Stacy BrownMt Juliet$719K
- Dana WebberKnoxville$499K
- Brandy BiedermanHixson$448K
- Cynthia MillerMurfreesboro$384K
- Tamera ThoenerNashville$254K
- April SwonerHermitage$246K
- Jennifer WilliamsNashville$213K
- Chantil JeffreysGermantown$195K
- Laura PorchCordova$148K
- Lori LankfordNashville$148K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.